Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanne Elming

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Ugeskrift for Laeger|June 3, 2005
[Cardiac arrest following treatment with non-cardiologic QT-interval-increasing medications]Safar Al-Amood, Hanne Elming
Ugeskrift for Laeger|October 30, 2014
[Malignant melanoma with metastatic melanoma to the heart]Martin Frydland, Hanne Elming, Ole Ahlehoff
Ugeskrift for Laeger|June 16, 2023
Annika Wattez, Hanne Elming, Flemming Javier Olsen
Ugeskrift for Laeger|February 20, 2002
[Why is QT interval interesting?]Hanne Elming, Jesper Sonne, Henrik K F Lublin
Expert Opinion on Emerging Drugs|June 7, 2005
New antiarrhythmic agents for atrial fibrillation and atrial flutterRedi Pecini, Hanne Elming, Ole Dyg Pedersen, et al.
Clinical Cardiology|May 29, 2003
The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilideBente Brendorp, Hanne Elming, Li Jun, et al.
Cardiac Electrophysiology Review|July 13, 2002
QTc interval in the assessment of cardiac riskHanne Elming, Bente Brendorp, Lars Køber, et al.
European Journal of Heart Failure|April 18, 2002
Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failureBente Brendorp, Hanne Elming, Li Jun, et al.
Expert Opinion on Pharmacotherapy|June 5, 2003
Dofetilide: a new drug to control cardiac arrhythmiaHanne Elming, Bente Brendorp, Ole Dyg Pedersen, et al.
Expert Review of Cardiovascular Therapy|March 20, 2004
Can antiarrhythmic drugs save lives in patients with congestive heart failure?Bente Brendorp, Ole Dyg Pedersen, Hanne Elming, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Ugeskrift for Laeger|June 3, 2005
[Cardiac arrest following treatment with non-cardiologic QT-interval-increasing medications]Safar Al-Amood, Hanne Elming
Ugeskrift for Laeger|October 30, 2014
[Malignant melanoma with metastatic melanoma to the heart]Martin Frydland, Hanne Elming, Ole Ahlehoff
Ugeskrift for Laeger|June 16, 2023
Annika Wattez, Hanne Elming, Flemming Javier Olsen
Ugeskrift for Laeger|February 20, 2002
[Why is QT interval interesting?]Hanne Elming, Jesper Sonne, Henrik K F Lublin
Expert Opinion on Emerging Drugs|June 7, 2005
New antiarrhythmic agents for atrial fibrillation and atrial flutterRedi Pecini, Hanne Elming, Ole Dyg Pedersen, et al.
Clinical Cardiology|May 29, 2003
The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilideBente Brendorp, Hanne Elming, Li Jun, et al.
Cardiac Electrophysiology Review|July 13, 2002
QTc interval in the assessment of cardiac riskHanne Elming, Bente Brendorp, Lars Køber, et al.
European Journal of Heart Failure|April 18, 2002
Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failureBente Brendorp, Hanne Elming, Li Jun, et al.
Expert Opinion on Pharmacotherapy|June 5, 2003
Dofetilide: a new drug to control cardiac arrhythmiaHanne Elming, Bente Brendorp, Ole Dyg Pedersen, et al.
Expert Review of Cardiovascular Therapy|March 20, 2004
Can antiarrhythmic drugs save lives in patients with congestive heart failure?Bente Brendorp, Ole Dyg Pedersen, Hanne Elming, et al.
Pageof 5